Compare EMBJ & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBJ | PCVX |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | Brazil | United States |
| Employees | 20744 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.6B |
| IPO Year | N/A | 2020 |
| Metric | EMBJ | PCVX |
|---|---|---|
| Price | $62.79 | $57.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $84.00 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 1.2M | 986.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.60 | N/A |
| P/E Ratio | $159.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.28 | $28.09 |
| 52 Week High | $80.75 | $65.00 |
| Indicator | EMBJ | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 43.61 |
| Support Level | $60.76 | $52.04 |
| Resistance Level | $65.81 | $58.95 |
| Average True Range (ATR) | 2.03 | 2.05 |
| MACD | -0.48 | -0.61 |
| Stochastic Oscillator | 18.06 | 19.29 |
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.